Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04781738
Other study ID # RMB-0218-17
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 15, 2018
Est. completion date February 2022

Study information

Verified date February 2021
Source Rambam Health Care Campus
Contact Lea Bentur, MD
Phone +972-4-7774360
Email l_bentur@rambam.health.gov.il
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To investigate the long term functional capacity and quality of life of patients with a history of vascular ring whether they did or did not have corrective surgery. Patients will perform pulmonary function test, 6 minute walk test, cardiopulmonary exercise test and will fill a quality of life questionnaire.


Description:

Vascular rings are congenital vascular anomalies of the aortic arch that compress the esophagus and the trachea. The most common vascular rings are double aortic arch and right aortic arch with left ligamentum. Pulmonary artery sling is less common. Another cause of tracheal compression occurring only in infants is the innominate artery compression syndrome. When patients are symptomatic, surgical correction should be performed. data regarding long term functional capacity and quality of life is lacking. our aim is to investigate the long term functional capacity and quality of life of patients with history of vascular ring whether they did or did not have corrective surgery. Methods: a prospective study evaluating functional capacity and quality of life the patients will perform pulmonary function test, 6 minute walk test, cardiopulmonary exercise test and will fill a quality of life questionnaire (sf-36).


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date February 2022
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 5 Years and older
Eligibility Inclusion Criteria: - patients with history of vascular ring Exclusion Criteria: - refusal to participate - inability to complete cardiopulmonary testing

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Cardiopulmonary exercise test
CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with no resistance warmup lasting 1-3 minutes followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment by successive stages Six minute walk test - patients will be instructed to walk as far as possible for six minutes in a 30-meter long enclosed corridor with a flat and hard surface, marked at every meter. Meters will be calculated at the end of the test. SF-36 is a questionnaire that contains eight domains - physical functioning (10 items); role limitations due to physical functioning (4 items); role limitations due to emotional problems (3 items); energy and vitality (4 items); mental health (5 items); social functioning (2 items); bodily pain (2 items); and general health perceptions (5 items). Scores are summed for each domain and were transformed into scores of between 0 (worst possible health state) to 100 (best possible health state).

Locations

Country Name City State
Israel Rambam health care campus Haifa

Sponsors (1)

Lead Sponsor Collaborator
Rambam Health Care Campus

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Exercise capacity Oxygen uptake evaluated by cardiopulmonary exercise testing (CPET) Measured continuously during 15 minutes of the exercise test (CPET)
Secondary Six minute walk test The distance gained after six minute of habitual walking. Six minutes of evaluation, completed pre cardiopulmonary exercise test (CPET)
Secondary Quality of life - SF-36 The calculated result of SF-36 questionnaire Five minutes of evaluation, completed pre cardiopulmonary exercise test (CPET)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06409299 - Enhancing Lung Health in Kids With Structural Lung Damage and Malformations: Azithromycin (AZI) for Airway Infection Prevention Phase 3